DOW JONES21,052.53-360.91 -1.69%
S&P 5002,488.65-38.25 -1.51%
NASDAQ7,373.08-114.23 -1.53%

Alnylam Pharmaceuticals Q4 EPS $(1.98) Beats $(2.23) Estimate, Sales $71.681M Miss $72M Estimate

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported quarterly losses of $(1.98) per share which beat the analyst consensus estimate of $(2.23) by 11.21 percent. This is a 8.79 percent decrease over losses of $(1.82) per share

Benzinga · 02/06/2020 13:18

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported quarterly losses of $(1.98) per share which beat the analyst consensus estimate of $(2.23) by 11.21 percent. This is a 8.79 percent decrease over losses of $(1.82) per share from the same period last year. The company reported quarterly sales of $71.681 million which missed the analyst consensus estimate of $72 million by 0.44 percent. This is a 240.80 percent increase over sales of $21.033 million the same period last year.